EV Biologics, Inc (YECO) Fair Value & Analysis
Healthcare · US · Market cap $2.0K
EV Biologics, Inc
YECO · US
Fair value as of: Jun 26, 2026
From 3 valuation models · updated 7 days ago
Share price −98.7% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.0002 – $0.1000 · the $0.0002 price screens below the $0.0002 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
EV Biologics, Inc (YECO) currently trades at $0.0002, while our model-based Fair Value estimate is $0.0002 — implying the stock looks roughly 0.0% undervalued today. We read business quality at 36/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, EV Biologics, Inc generated revenue of $9.5M at a net margin of -5.8%. Net debt stands at $1.5M. Fundamentals as of Jun 26, 2026
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
EV Biologics, Inc., a biotechnology company, engages in the commercial development of extracellular vesicles (EVs) as biological modalities for diagnostics and therapeutics. It is involved in developing vaccines, therapeutics, and cures based on its proprietary multifunctional EV platform. The company also focuses on developing human mesenchymal and other stem cell, and cell-derived products to market in the cosmetic and biopharmaceutical spaces. The company was formerly known as Yulong Eco-Materials Limited and changed its name to EV Biologics, Inc. in August 2020. EV Biologics, Inc. was incorporated in 2011 and is headquartered in Cheyenne, Wyoming.
Revenue & earnings trend
FY2016 – FY2024 · reported fiscal years
EV Biologics, Inc reported revenue of $178K in FY2024 versus $9.5M in FY2016, a compound −39.2%/yr. Reported net income was −$299K in FY2024.
Is YECO fairly valued? → Check now
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is EV Biologics, Inc (YECO) undervalued?
What is the fair value of YECO?
What is the quality score of YECO?
What is the revenue of EV Biologics, Inc (YECO)?
What is the net profit margin of YECO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.